Published in Nucl Med Commun on September 01, 2011
(18)F-FDG PET in the evaluation of acuity of deep vein thrombosis. Clin Nucl Med (2012) 0.88
The role of molecular imaging in diagnosis of deep vein thrombosis. Am J Nucl Med Mol Imaging (2014) 0.84
Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma. Eur Radiol (2013) 0.83
The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations. Front Oncol (2016) 0.83
FDG-Avid Portal Vein Tumor Thrombosis from Hepatocellular Carcinoma in Contrast-Enhanced FDG PET/CT. Asia Ocean J Nucl Med Biol (2015) 0.76
18F-fluorodeoxyglucose positron emission tomography-computed tomography finding of left gonadal vein thrombosis in a case of renal cell carcinoma. Indian J Nucl Med (2016) 0.75
Inferior Vena Caval Tumor Thrombus in Giant Cell Tumor of Sacrum - An Unusual Complication Treated with Multimodality Management. J Orthop Case Reports (2016) 0.75
Role of fluorine-18 fluorodeoxyglucose positron emission tomography in a case of renal cell carcinoma to differentiate tumor thrombus from bland thrombus. Indian J Nucl Med (2015) 0.75
Multifocal Intrahepatic Artery Aneurysm with FDG-avid Thrombosis Simulating Metastasis: Report of a Rare Case. J Clin Exp Hepatol (2016) 0.75
Imaging findings of pelvic tumor thrombosis extending from sacral bone metastasis of adrenocortical carcinoma. Case Rep Radiol (2012) 0.75
Vascular thrombosis as a cause of abdominal pain in a patient with neuroendocrine carcinoma of pancreas: Findings on (68)Ga-DOTANOC PET/CT. Indian J Nucl Med (2012) 0.75
Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther (2016) 0.75
Cardiac Magnetic Resonance for Evaluating Catheter Related FDG Avidity. Case Rep Radiol (2016) 0.75
(18)F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scan Finding of Portal Venous Tumor Thrombus in a Case of Primary Gastric Malignancy. Indian J Nucl Med (2017) 0.75
Intense 18F-FDG uptake in an organizing right atrial thrombus mimicking malignancy. Radiol Case Rep (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity (2006) 2.95
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol (2002) 2.45
Pak protein kinases and their role in cancer. Cancer Metastasis Rev (2009) 2.44
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol (2009) 2.39
MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res (2008) 2.32
Significant small-bowel lesions detected by alternative diagnostic modalities after negative capsule endoscopy. Gastrointest Endosc (2008) 2.32
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (2009) 2.31
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology (2012) 2.23
Modified Trachlight for management of difficult pediatric airway. Paediatr Anaesth (2008) 2.19
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
Genomic instability and enhanced radiosensitivity in Hsp70.1- and Hsp70.3-deficient mice. Mol Cell Biol (2004) 2.05
Tc-99m ethylcysteinate dimer SPECT in the differential diagnosis of dementias. Neurol India (2010) 2.04
MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol (2010) 2.03
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Suicide an emerging public health problem: evidence from rural Haryana, India. Indian J Public Health (2013) 2.03
Cystatin C-based glomerular filtration rate estimating equations in early chronic kidney disease. Indian Pediatr (2014) 2.02
Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res (2006) 2.00
Metastasis tumor antigens, an emerging family of multifaceted master coregulators. J Biol Chem (2006) 2.00
Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell (2004) 1.93
Taxonomic studies on genus Tetramorium Mayr (Hymenoptera, Formicidae) with report of two new species and three new records including a tramp species from India with a revised key. Zookeys (2012) 1.92
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
Mammalian Rad9 plays a role in telomere stability, S- and G2-phase-specific cell survival, and homologous recombinational repair. Mol Cell Biol (2006) 1.84
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene (2003) 1.78
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res (2006) 1.72
Retracted Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. J Biol Chem (2010) 1.71
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem (2008) 1.66
Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res (2009) 1.66
MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci U S A (2006) 1.66
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem (2005) 1.65
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2013) 1.63
Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging (2014) 1.63
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci (2006) 1.63
Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT. Clin Nucl Med (2008) 1.61
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol (2004) 1.61
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol (2010) 1.60
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol (2004) 1.59
P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res (2006) 1.58
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep (2013) 1.57
Retracted Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. J Biol Chem (2009) 1.56
Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer (2010) 1.54
Thyroid scintigraphy in detecting dual ectopic thyroid: a review. Eur J Nucl Med Mol Imaging (2008) 1.54
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. J Biol Chem (2009) 1.52
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood (2008) 1.52
Community Perception and Client Satisfaction about the Primary Health Care Services in an Urban Resettlement Colony of New Delhi. Indian J Community Med (2008) 1.52
N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem (2009) 1.52
Nuclear receptor coregulators in cancer biology. Cancer Res (2009) 1.51
Dyke-Davidoff-Masson syndrome. Indian Pediatr (2008) 1.51
Hallmarks of mechanochemistry: from nanoparticles to technology. Chem Soc Rev (2013) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal (2007) 1.48
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Pediatric heart transplantation for congenital and restrictive cardiomyopathy. Ann Thorac Surg (2013) 1.47
Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med (2011) 1.47
Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res (2007) 1.47
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
Structural basis for processivity and single-strand specificity of RNase II. Mol Cell (2006) 1.44
Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett (2005) 1.44
Human heterochromatin protein 1 isoforms HP1(Hsalpha) and HP1(Hsbeta) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Mol Cell Biol (2003) 1.44
Dual ectopic thyroid: case series and review of the literature. Clin Nucl Med (2007) 1.44
Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med (2010) 1.43
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett (2003) 1.43
MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal (2007) 1.43
Reactivity of brain tissue oxygen to change in cerebral perfusion pressure in head injured patients. Neurocrit Care (2009) 1.43
Persistent renin-angiotensin system activation after anti-reflux surgery and its management. J Pediatr Urol (2011) 1.43
Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosimetry (2005) 1.43
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Long term outcome of management of antenatally diagnosed pelvi-ureteric junction obstruction. Indian J Pediatr (2011) 1.41
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res (2005) 1.39
Direct radionuclide cystography by supra-pubic puncture: comparison with conventional voiding cystourethrography. Nucl Med Commun (2004) 1.39
Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. Indian J Gastroenterol (2002) 1.39
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
National leadership: driving forward the updated Global Strategy for Women's, Children's and Adolescents' Health. BMJ (2015) 1.38
Steering estrogen signals from the plasma membrane to the nucleus: two sides of the coin. J Cell Physiol (2006) 1.36
Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury. J Neurosurg (2008) 1.35
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer (2006) 1.34
The molecular basis for ligand specificity in a mouse olfactory receptor: a network of functionally important residues. J Biol Chem (2006) 1.34
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34